Divi’s Labs has signed a confidential long-term agreement with a global pharma company for advanced intermediates supply.
“Under the long-term agreement, the company will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties. The company expects meaningful revenue contribution from this long-term agreement. In view of the confidentiality agreement signed, we are not permitted to disclose the name of customer and any quantitative information pertaining to the agreement,” the pharma company said in a stock exchange filing.
The company also plans capacity addition at its manufacturing facilities with an estimated investment between Rs 650 crore and Rs 700 crore, to be funded from internal accruals, Divi said.
